Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) released its earnings results on Monday. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($2.05) by $1.74, FiscalAI reports.
Alaunos Therapeutics Price Performance
TCRT stock traded down $0.03 during mid-day trading on Monday, reaching $1.60. 61,107 shares of the company’s stock were exchanged, compared to its average volume of 2,209,315. Alaunos Therapeutics has a 12-month low of $0.72 and a 12-month high of $4.50. The company has a market cap of $5.30 million, a price-to-earnings ratio of -0.84 and a beta of -1.02. The stock’s 50 day moving average is $1.64 and its 200 day moving average is $2.28.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on TCRT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alaunos Therapeutics in a research note on Friday. TD Cowen initiated coverage on shares of Alaunos Therapeutics in a research report on Friday. They set a “buy” rating for the company. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold”.
About Alaunos Therapeutics
Alaunos Therapeutics was a biotechnology company focused on developing engineered T-cell therapies for cancer. Its research centered on T-cell receptor (TCR) therapies designed to help a patient’s immune cells recognize and attack tumors. The company’s main program investigated genetically modified T cells targeting cancer-associated mutations, including mutations in the KRAS gene, in patients with solid tumors. Its approach used a library of TCRs intended to recognize different tumor mutations.
Recommended Stories
- Five stocks we like better than Alaunos Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
